C-reactive protein levels in patients at cardiovascular risk: EURIKA study

BMC Cardiovasc Disord. 2014 Feb 24;14:25. doi: 10.1186/1471-2261-14-25.

Abstract

Background: Elevated C-reactive protein (CRP) levels are associated with high cardiovascular risk, and might identify patients who could benefit from more carefully adapted risk factor management. We have assessed the prevalence of elevated CRP levels in patients with one or more traditional cardiovascular risk factors.

Methods: Data were analysed from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA, ClinicalTrials.gov Identifier: NCT00882336), which included patients (aged ≥50 years) from 12 European countries with at least one traditional cardiovascular risk factor but no history of cardiovascular disease. Analysis was also carried out on the subset of patients without diabetes mellitus who were not receiving statin therapy.

Results: In the overall population, CRP levels were positively correlated with body mass index and glycated haemoglobin levels, and were negatively correlated with high-density lipoprotein cholesterol levels. CRP levels were also higher in women, those at higher traditionally estimated cardiovascular risk and those with greater numbers of metabolic syndrome markers. Among patients without diabetes mellitus who were not receiving statin therapy, approximately 30% had CRP levels ≥3 mg/L, and approximately 50% had CRP levels ≥2 mg/L, including those at intermediate levels of traditionally estimated cardiovascular risk.

Conclusions: CRP levels are elevated in a large proportion of patients with at least one cardiovascular risk factor, without diabetes mellitus who are not receiving statin therapy, suggesting a higher level of cardiovascular risk than predicted according to conventional risk estimation systems.

Trial registration: ClinicalTrials.gov Identifier: NCT00882336.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / blood
  • Body Mass Index
  • C-Reactive Protein / analysis*
  • Cardiovascular Diseases / blood*
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / epidemiology
  • Cholesterol, HDL / blood
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / epidemiology
  • Dyslipidemias / blood
  • Dyslipidemias / epidemiology
  • Europe / epidemiology
  • Female
  • Glycated Hemoglobin / analysis
  • Humans
  • Inflammation Mediators / blood*
  • Male
  • Metabolic Syndrome / blood
  • Metabolic Syndrome / epidemiology
  • Middle Aged
  • Risk Assessment
  • Risk Factors
  • Up-Regulation

Substances

  • Biomarkers
  • Cholesterol, HDL
  • Glycated Hemoglobin A
  • Inflammation Mediators
  • hemoglobin A1c protein, human
  • C-Reactive Protein

Associated data

  • ClinicalTrials.gov/NCT00882336